世界最新医学信息文摘(连续型电子期刊)
世界最新醫學信息文摘(連續型電子期刊)
세계최신의학신식문적(련속형전자기간)
World Latest Medicine Information
2015年
12期
36-37,35
,共3页
武永存%要雪品%李曼%王立媛%白瑞烁
武永存%要雪品%李曼%王立媛%白瑞爍
무영존%요설품%리만%왕립원%백서삭
食管癌%三维适形放疗%紫杉醇脂质体
食管癌%三維適形放療%紫杉醇脂質體
식관암%삼유괄형방료%자삼순지질체
esophagus cancer%3-D conformal radiotherapy%Paclitaxel Liposome
目的:观察紫杉醇脂质体联合顺铂同期三维适形放疗治疗中晚期食管癌的疗效及毒副反应。方法:78例食管癌患者随机分为治疗组和对照组,治疗组用TP方案(紫杉醇脂质体135 mg辕m2,d1;顺铂25 mg辕m2,d2-5静脉滴注,28d为1周期,放疗期间用2周期)加三维适形放疗,与单纯放疗组进行对照。两组放疗剂量相同(DT 66 Gy)。按WHO标准评价疗效和毒副反应。结果:治疗组近期疗效率为84.6豫(33辕39),对照组为64.1豫(25辕39),比较差异有统计学意义,P<0.05。主要不良反应为I-Ⅱ度骨髓抑制、放射性食管反应、恶心、呕吐、便秘与脱发。结论:三维适形放疗联合同期TP方案化疗,可明显提高食管癌放疗患者的近期疗效,但放射性不良反应也相应增加。
目的:觀察紫杉醇脂質體聯閤順鉑同期三維適形放療治療中晚期食管癌的療效及毒副反應。方法:78例食管癌患者隨機分為治療組和對照組,治療組用TP方案(紫杉醇脂質體135 mg轅m2,d1;順鉑25 mg轅m2,d2-5靜脈滴註,28d為1週期,放療期間用2週期)加三維適形放療,與單純放療組進行對照。兩組放療劑量相同(DT 66 Gy)。按WHO標準評價療效和毒副反應。結果:治療組近期療效率為84.6豫(33轅39),對照組為64.1豫(25轅39),比較差異有統計學意義,P<0.05。主要不良反應為I-Ⅱ度骨髓抑製、放射性食管反應、噁心、嘔吐、便祕與脫髮。結論:三維適形放療聯閤同期TP方案化療,可明顯提高食管癌放療患者的近期療效,但放射性不良反應也相應增加。
목적:관찰자삼순지질체연합순박동기삼유괄형방료치료중만기식관암적료효급독부반응。방법:78례식관암환자수궤분위치료조화대조조,치료조용TP방안(자삼순지질체135 mg원m2,d1;순박25 mg원m2,d2-5정맥적주,28d위1주기,방료기간용2주기)가삼유괄형방료,여단순방료조진행대조。량조방료제량상동(DT 66 Gy)。안WHO표준평개료효화독부반응。결과:치료조근기료효솔위84.6예(33원39),대조조위64.1예(25원39),비교차이유통계학의의,P<0.05。주요불량반응위I-Ⅱ도골수억제、방사성식관반응、악심、구토、편비여탈발。결론:삼유괄형방료연합동기TP방안화료,가명현제고식관암방료환자적근기료효,단방사성불량반응야상응증가。
Objective:To observe the effect of three dimensional conformal radiotherapy combined with concurrent TP regimen in the treatment of locally advanced esophageal carcinoma.Methods:All 78 esophagus cancer patients were divided into treat-ment group and the control group.The treatment group treated with TP (Paclitaxel Liposome 135 mg/m2,d1,cisplatin 25 mg/m2,d2-5,28d 1 cycle,three dimensional radiotherapy was performed radiotherapy dosage DT66 Gy.Results:For treatment group curative effective rate was 84.6% (33/39),for control group was 64.1% (25/39),P<0.05.The main side reaction was I-II degree marrow suppresses.vomit constipation and lose hair.Conclusion:Three dimensional radiotherapy combined with TP chemotherapy, may enhance short-term curative effect obviously but the side reaction also increase in esophageal cancer pa-tients.